BioAegis Therapeutics Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 11

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $22M

  • Investors
  • 2

BioAegis Therapeutics General Information

Description

Operator of a clinical-stage drug development platform intended to facilitate the treatment of inflammation and infectious diseases. The company's platform specializes in the research and development of drugs to restore plasma gelsolin - innate immunity that provides an immunotherapeutic approach to fighting pathogens, enabling hospitals to begin treatment and result in a high likelihood of successful treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • Commercialization Center for Innovative Technology
  • 675 US Highway One
  • North Brunswick, NJ 08902
  • United States
+1 (973) 000-0000

BioAegis Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioAegis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 22-Mar-2022 $22M 000.00 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C) 31-Dec-2021 0000 000.00 Completed Clinical Trials - Phase 2
7. Later Stage VC 07-Oct-2020 000 000.00 Completed Clinical Trials - Phase 2
6. Debt - PPP 28-Apr-2020 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 01-Aug-2018 00.00 000.00 000.00 Completed Clinical Trials - General
4. Grant 09-Jul-2016 000 000.00 Completed Clinical Trials - General
3. Later Stage VC 11-Mar-2016 00.00 000.00 0000 Completed Startup
2. Early Stage VC (Series A) 01-Jan-2015 $8.04M $11M 0000 Completed Startup
1. Angel (individual) 08-Feb-2013 $3M $3M Completed Startup
To view BioAegis Therapeutics’s complete valuation and funding history, request access »

BioAegis Therapeutics Executive Team (15)

Name Title Board Seat Contact Info
Susan Levinson Ph.D Co-Founder, Board Member & Chief Executive Officer
Valerie Ceva Co-Founder, Board Member & Chief Operating Officer
Steven Cordovano Co-Founder & Vice President of Corporate Development and Communications
B. Taylor Thompson MD Clinical Advisory Board Member
John Kellum MD Clinical Advisory Board Member
You’re viewing 5 of 15 executive team members. Get the full list »

BioAegis Therapeutics Board Members (6)

Name Representing Role Since
Kris Vinckier BioAegis Therapeutics Board Member 000 0000
Mark DiNubile MD BioAegis Therapeutics Chief Medical Officer & Board Member 000 0000
Susan Levinson Ph.D BioAegis Therapeutics Co-Founder, Board Member & Chief Executive Officer 000 0000
You’re viewing 3 of 6 board members. Get the full list »

BioAegis Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioAegis Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
European Investment Fund Fund of Funds Minority 000 0000 000000 0
National Institute Of Allergy and Infectious Diseases Government 000 0000 000000 0
To view BioAegis Therapeutics’s complete investors history, request access »